Abstract
Anti-phospholipid antibodies are common in patients in the Hopkins' Lupus Cohort: 47% have anti-cardiolipin, 32.5% anti-beta(2)-glycoprotein I and 26% lupus anticoagulant (by dRVVT confirmatory testing). Systemic lupus erythematosus patients with the lupus anticoagulant at baseline have a 50% chance of a deep venous thrombosis/pulmonary embolus in the next 20 years. Anti-phospholipid antibodies differ in their association with thrombosis: the lupus anticoagulant is most strongly associated with arterial and venous thrombosis and is the only anti-phospholipid antibody associated with myocardial infarction. Anti-phospholipid antibodies are not associated with atherosclerosis.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Anticardiolipin / immunology
-
Antibodies, Antiphospholipid / immunology*
-
Cohort Studies
-
Female
-
Humans
-
Longitudinal Studies
-
Lupus Coagulation Inhibitor / immunology*
-
Lupus Erythematosus, Systemic / complications
-
Lupus Erythematosus, Systemic / immunology*
-
Male
-
Myocardial Infarction / epidemiology
-
Myocardial Infarction / etiology
-
Pulmonary Embolism / epidemiology
-
Pulmonary Embolism / etiology
-
Thrombosis / epidemiology
-
Thrombosis / etiology
-
Time Factors
-
beta 2-Glycoprotein I / immunology
Substances
-
Antibodies, Anticardiolipin
-
Antibodies, Antiphospholipid
-
Lupus Coagulation Inhibitor
-
beta 2-Glycoprotein I